Kwang Dong Pharmaceutical Co., Ltd.

KRX:009290.KS

5850 (KRW) • At close October 17, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) KRW.

20232022202120202019201820172016201520142013201220112010200920082007
Revenue 1,514,454.1481,431,545.2551,338,181.5541,243,769.5961,238,254.6961,180,219.9471,141,565.9211,056,428.809955,453.632522,274.345468,384.62332,641.298313,986.323289,434.907276,585.2276,172.8250,523.205
Cost of Revenue 1,219,335.3741,149,497.5291,063,928.866986,061.06979,586.865938,626.057894,456.613808,717.55722,809.973328,239.818297,951.611197,027.031177,279.111163,000.185156,612.004155,617.207140,364.17
Gross Profit 295,118.774282,047.727274,252.688257,708.536258,667.831241,593.889247,109.308247,711.26232,643.658194,034.527170,433.009135,614.268136,707.212126,434.722119,973.196120,555.593110,159.035
Gross Profit Ratio 0.1950.1970.2050.2070.2090.2050.2160.2340.2430.3720.3640.4080.4350.4370.4340.4370.44
Reseach & Development Expenses 15,274.819,678.2048,321.9835,956.9965,338.94,178.9171,513.2485,025456.55500000020090
General & Administrative Expenses 15,170.54314,783.61613,127.27511,453.10814,552.20613,861.34214,614.71914,985.1313,147.01511,765.4910,435.3639,628.4519,506.27811,659.12611,305.47812,334.2249,328.272
Selling & Marketing Expenses 133,099.66126,130.895124,112.118112,797.187114,285.176107,508.854118,455.799115,729.72497,744.80579,523.76665,551.23747,373.82747,186.97740,737.2441,519.36642,425.86735,912.156
SG&A 235,784.9140,914.511137,239.393124,250.295128,837.382121,370.196133,070.518130,714.854110,891.8291,289.25675,986.657,002.27856,693.25552,396.36652,824.84454,760.09145,240.428
Other Expenses -2,780.95893,210.5783,755.62980,910.53182,688.311748.763-820.386-2,794.711-1,030.227-2,241.281-1,283.603771.299951.774-744.048-2,106.1951,566.861-348.373
Operating Expenses 253,840.668243,803.285229,317.005211,117.822216,864.593207,648.986211,371.858203,322.313181,777.196143,575.278126,043.44599,273.83696,561.97488,135.1887,001.20890,669.20379,599.425
Operating Income 41,278.10638,244.44244,935.68446,590.71341,803.23833,944.90335,737.4544,388.94650,866.46250,459.24944,389.56336,340.43238,614.54438,299.54332,971.98829,886.39330,559.61
Operating Income Ratio 0.0270.0270.0340.0370.0340.0290.0310.0420.0530.0970.0950.1090.1230.1320.1190.1080.122
Total Other Income Expenses Net 6,422.373-1,953.725-10,606.99916,360.257-5,033.643-2,549.009-2,386.634-4,196.4-1,148.684-3,108.847-4,562.8341,179.191522.881-824.15-246.3152,805.0571,030.79
Income Before Tax 47,700.47936,290.71634,328.68562,950.9736,769.59431,395.89433,350.81540,192.54749,717.77847,350.40239,826.72937,519.62240,668.11837,475.39232,725.67332,691.44731,590.4
Income Before Tax Ratio 0.0310.0250.0260.0510.030.0270.0290.0380.0520.0910.0850.1130.130.1290.1180.1180.126
Income Tax Expense 9,647.5749,590.0178,787.9417,349.00314,113.7939,421.47410,267.72812,292.95213,634.61512,287.14517,828.1459,758.05910,774.27212,261.6829,539.84711,284.6397,427.92
Net Income 36,965.56224,173.93124,019.07145,369.77323,058.31622,345.01923,196.1328,062.80135,015.30835,043.97222,037.36927,823.69629,923.09525,213.7123,185.82621,406.80924,162.48
Net Income Ratio 0.0240.0170.0180.0360.0190.0190.020.0270.0370.0670.0470.0840.0950.0870.0840.0780.096
EPS 913.39588.45584.681,119.49581.72551572692868869538668683552497447489
EPS Diluted 913.39588.45584.331,119.49581.72551572692868869538668683552497447489
EBITDA 54,114.08456,756.92163,946.92271,014.17265,168.47354,395.80351,268.71758,509.00262,987.34658,060.42652,583.35846,541.26949,459.59245,858.69741,113.19744,282.32241,682.626
EBITDA Ratio 0.0360.040.0480.0570.0530.0460.0450.0550.0660.1110.1120.140.1580.1580.1490.160.166